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We used a human cDNA macroarray containing various
oncogenes and tumour suppressor genes to assess gene expression
profiles in early-passage Jurkat T lymphocytes treated with
clinically relevant concentrations of the antitumour antibiotic
daunorubicin. Several oncogenes and tumour suppressor genes
were either up- or down-regulated depending on the daunorubicin
concentration used. The expression levels of some of these genes
were confirmed by semi-quantitative reverse transcriptase–PCR.
We also compared the changes in cell-cycle distribution and the
apoptotic morphological characteristics of the cells treated with
daunorubicin, using flow cytometry and fluorescence microscopy.
Exposure to 182 nM daunorubicin (its IC75 in Jurkat T cells:
where IC75 is the drug concentration that inhibits growth by 75%)
resulted in cell-cycle arrest in G1 and almost immediate apoptosis.
In contrast, decreasing the drug concentration to 91 nM (close
to the IC50) caused G2 arrest and cell senescence-like growth
arrest, whereas features of apoptosis and necrosis appeared only
after longer incubation times. Gene expression profiles, cell-
cycle distribution, the presence of DNA damage and the time-
dependent response of Jurkat T cells to cell death were correlated
clearly. The general behaviour of the genes suggests that cell-
cycle arrest and cell death follow distinct pathways depending on
drug concentration.
Key words: anthracycline, array, cell cycle, Jurkat T lymphocyte,
transcriptome.
INTRODUCTION
In the presence of several DNA-binding drugs, tumour cells
can suffer growth arrest and death [1–3]. The regulation of
transcription plays a critical role in the control of growth
and differentiation of normal and tumour cells (see [4,5] and
references therein). Therefore there is a widespread interest in
drugs, which can bind to DNA and affect the final destiny
of tumour cells through the inhibition of gene transcription
[6–10]. Changes in the transcription levels of certain genes,
such as oncogenes or tumour-suppressor genes, may inhibit
the development of tumours after drug treatment. Evidence is
mounting that drug-induced cell death programmes can be either
activated or suppressed depending on the cell type and the
characteristics of antitumour agents [11–14].
Large-scale measurement of gene expression should provide
new keys to gain more insights into cells treated with anticancer
drugs [6,12,15]. DNA array technology permits the simultaneous
measurement of the expression levels of thousands of genes. It can
provide a comprehensive framework to determine the genes that
are involved in changes in cell-cycle progression after treatment
with DNA-binding drugs [6]. The patterns observed in genome-
wide expression experiments may indicate the status of cellular
processes and drug effects, although the correct interpretation of
these results may be hindered by the interrelation between cell-
cycle pathways, which makes it difficult to discriminate direct and
indirect effects.
It is accepted widely that cell death after DNA damage by
antitumour drugs occurs mainly due to programmed cell death
(apoptosis). However, it has been observed that apoptosis is only
the primary mediator of cell killing in some tumours [2]. The
influence of the p53 gene product, a key element in apoptotic
response, has been characterized in depth [16,17]. The p53 gene
is a critical component of two distinct cellular responses to DNA
damage, the induction of a reversible arrest at the G1/S cell-
Abbreviations used: BrdUrd, 5-bromo-2′-deoxyuridine; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; IC75, drug concentration that inhibits
growth by 75%; RT, reverse transcriptase; SA-β-gal, senescence-associated β-galactosidase.
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cycle checkpoint and the activation of apoptosis [2,16]. It is also
involved in the halt in the G2/M checkpoint [18]. Nonetheless, in
some tumour cells, the final apoptotic response may depend on
the transcription levels of other genes [2,19–22]. The elucidation
of the factors that regulate different aspects of treatment-induced
apoptosis and alternative ways of cell killing should improve the
efficacy of anticancer therapy [2,11,23].
We aimed to study the correlation between the transcript profile
of Jurkat T cells in the presence of a DNA-binding drug, and the
drug activities through the resulting gene expression levels, with
special emphasis on the link between the cell-cycle distribution
and gene transcription profiles. We explored the sensitivity of gene
expression in p53+/+ Jurkat T lymphocytes after treatment with
daunorubicin. This is an anthracycline antibiotic used primarily
in the treatment of acute myeloid leukaemia [7]. It recognizes
(C + G)-rich DNA sequences specifically [24], and acts as both
a transcription inhibitor [9,15] and a topoisomerase II inhibitor
[25]. In the present paper, we compare experiments performed
in parallel on the gene expression patterns of proliferating
Jurkat T cells and daunorubicin-treated cells using macroarrays
of cDNAs. Specific features of gene expression responses are
identified, which are dependent on several key pathways. We also
tested whether drug-induced quiescence and death in Jurkat T
lymphocytes were associated with changes in the transcription
profile of oncogenes and tumour suppressor genes, since several
transcription regulators and components of signal-transduction
pathways can regulate apoptosis [26].
MATERIALS AND METHODS
Cell line and culture conditions
Early-passage Jurkat T lymphocytes (A.T.C.C. TIB-152, clone
E6-1, with no more than three serial subcultures after arrival)
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were maintained in RPMI 1640 medium (Gibco BRL, Invitrogen,
Prat de Llobregat, Spain), supplemented with 10% (v/v) foetal
calf serum (Gibco BRL) and 2 mM L-glutamine (Gibco BRL), at
37 ◦C in a humidified atmosphere with 5% CO2. Viable cell
number was determined using the exclusion of Trypan Blue
dye (Fluka, Madrid, Spain) and a haemocytometer. Solutions
containing 500 µM daunorubicin (Sigma) were prepared with
sterile 150 mM NaCl, maintained at − 20 ◦C, and brought to the
final concentration with RPMI 1640 medium just before use.
Human array experimental design
The Human Oncogene/Tumour Suppressor Atlas Array (BD
ClonTech, Palo Alto, CA, U.S.A.) was used to monitor changes
in the levels of transcription of 199 genes in Jurkat T lym-
phocytes, with various concentrations of the anticancer antibiotic
daunorubicin, compared with untreated cells. The annotated
function for all these genes, as well as their accession
numbers, can be found at the BD ClonTech homepage (http://
www.clontech.com/atlas). Of these genes, 190 are commonly
classified as oncogenes or tumour suppressor genes, whereas
nine are regarded as housekeeping genes. Experiments were
undertaken in triplicate and the results averaged. A database
consisting of the average raw data for all genes in the different
experiments and the processed (normalized) results, as sup-
plementary material, is available as online data at http://www.
BiochemJ.org/bj/372/bj3720703add.htm
RNA extraction and cDNA synthesis
Total RNA was isolated, after 4 h, from control cells (those to
which no drug was added) and from cells treated with 182 nM
daunorubicin (its IC75 in Jurkat T cells determined after 72 h
continuous treatment [27]; where IC75 is the drug concentration
that inhibits cell growth by 75%) or 91 nM daunorubicin (close
to the IC50). The UltraspecRNA isolation reagent (Biotecx,
Houston, TX, U.S.A.) was used following the procedure provided
by the vendor. RNA was digested with RNAse-free DNase I
(BD ClonTech) in the presence of RNAse inhibitors (RNasin ;
Promega), phenol-extracted and precipitated. The pellet was
dissolved in RNAse-free water, and the yield and the purity of
total RNA were assessed spectrophotometrically.
Approx. 5 µg of RNA was used to convert total RNA into
32P-labelled first-strand cDNA, using [α-32P]ATP and the gene-
specific CDS-primer mix for the Atlas array (BD ClonTech)
following the method provided by the vendor. The labelled cDNA
was purified from unincorporated [α-32P]ATP using a NucleoSpin
Column (BD ClonTech).
Human array hybridization
A set of Human Oncogene/Tumour Suppressor Atlas Arrays
(BD ClonTech), containing cDNAs of 199 genes, were used
for hybridization. Hybridization with the labelled probes
was performed, in triplicate, using ExpressHyb solution (BD
ClonTech) at 68 ◦C for 16 h. The arrays were rinsed with 2 × SSC
(300 mM sodium chloride 30 mM trisodium citrate, pH 7.0), 1%
(w/v) SDS and washed using 0.1 × SSC, 0.5% SDS at 68 ◦C for
30 min, and a final 5 min wash was performed in 200 ml of
2 × SSC at room temperature (25 ◦C). The Atlas Arrays were
exposed to an Imaging Screen-K (Bio-Rad) and analysed using a
Molecular Imager FX (Bio-Rad).
Expression profile analysis
For image processing, the intensity of the radioactive signals was
analysed using Quantity One 4.1.1 software (Bio-Rad), and the
peak areas were transferred into a standard spreadsheet program.
To analyse the differential gene expression in the absence and
in the presence of several concentrations of daunorubicin, the
background in each array was subtracted from the spot values,
and the average intensity of the housekeeping gene GAPDH
(glyceraldehyde-3-phosphate dehydrogenase), utilized widely as
control in transcription experiments, was used to normalize the
results and to adjust for differences in labelling and the quantities
of RNA. The nine control genes in the array gave similar
hybridization signals, including GAPDH, within a calculated 5%
error (see supplementary material).
After normalization, data for each gene were calculated as
the log2 of the expression ratio between ‘daunorubicin-treated’
and ‘control’ membranes. The J-Express software (MolMine AS,
Bergen, Norway) was used in the comparison of the expression
profiles. A post-normalization cut-off of 2.5-fold increase or
decrease in the expression ratio was used. There is no firm
theoretical basis for selecting a particular level of significance,
but a cut-off of 2-fold increase or decrease is used generally.
The number of genes analysed, which were clearly up- or down-
regulated was almost the same using a much stringent 4-fold cut-
off criteria (see the Results section and also the supplementary
material available on the Biochemical Journal web site).
Semi-quantitative reverse transcriptase (RT)–PCR
Changes in gene expression were verified by semi-quantitative
RT–PCR using GAPDH as an internal normalization standard.
Total RNA was isolated, after 4 h, from control cells (those
to which no drug was added) and the cells were treated with
different concentrations of daunorubicin as indicated in the
legends to Figures, and digested with DNase I as described above.
Subsaturating RT–PCR conditions were adjusted to 10 ng of total
RNA and 20–25 amplification cycles, with the annealing reactions
performed at 50 ◦C for 1 min, using the OneStep PCR kit (Qiagen,
Hilden, Germany) according to the manufacturer’s instructions.
The primers used (0.6 µM) are indicated in the legend to
Figure 3. PCR samples were electrophoresed in a 2% (w/v)
agarose gel, stained with ethidium bromide and quantified using
a Molecular Dynamics Densitometer.
Cell-cycle distribution and apoptosis
After treatment with daunorubicin for various periods of time,
the cells were harvested and stained with propidium iodide
(Sigma) as described elsewhere [28]. Nuclei were analysed with a
Coulter Epics-XL flow cytometer (Coulter Corporation, Hialeah,
FL, U.S.A.) at the ‘Serveis Cientifico-Tecnics’ (University of
Barcelona, Spain) using the 488 nm line of an argon laser
and standard optical emission filters. Percentages of cells at
each phase of the cell cycle were estimated from their DNA
content histograms after drug treatment. Apoptosis was quantified
and distinguished from necrosis by using the Annexin-V-Fluos
staining kit (Roche Diagnostics, Barcelona, Spain) and flow
cytometry as described in [29].
For morphological observation, approx. 104 daunorubicin-
treated Jurkat cells were spun on to microscope slides, stained
with 4,6-diamidino-2-phenylindole (Sigma) or with propidium
iodide plus Annexin-V-Fluos (Roche Diagnostics) and analysed
with a Carl Zeiss Axiophot fluorescence microscope. Apoptotic
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cells were identified by the presence of cytoplasmic shrinking and
nuclear condensation.
Quantification of cellular DNA fragmentation
Cell cultures were incubated for 16 h with 10 µM 5-bromo-
2′-deoxyuridine (BrdUrd) (Roche Diagnostics), harvested by
centrifugation and redissolved in fresh RPMI 1640 medium
(Gibco BRL). Thereafter, they were incubated with 92 or
182 nM daunorubicin for 4 or 10 h. Cells were lysed, and
the DNA fragments were detected using anti-DNA antibody
and anti-BrdUrd antibody conjugated to horseradish peroxidase
by using the Cellular DNA fragmentation ELISA kit (Roche
Diagnostics). Colour development was measured at 450 nm using
a SPECTRAmax-250 microplate reader (Molecular Devices,
Sunnyvale, CA, U.S.A.).
Senescence-associated β-galactosidase (SA-β-gal) staining and
DNA synthesis assays to detect senescent cells
After treatment with daunorubicin, cells were fixed in 3% (v/v)
formaldehyde and stained with fresh SA-β-gal stain solution
as described elsewhere [30], using X-Gal (5-bromo-4-chloro-3-
indolyl β-D-galactosidase) at pH 6.0. Senescence-like growth
arrest was determined as the percentage of SA-β-gal + cells
appraised by phase-contrast microscopy, after scoring 50–
100 cells for each control and daunorubicin-treated sample.
DNA synthesis was assayed as described elsewhere [31],
utilizing BrdUrd, anti-BrdUrd-POD (Roche Diagnostics) and a
colorimetric reaction using 4-Nitro Blue Tetrazolium chloride
(Roche Diagnostics), measured at 370 nm.
RESULTS
Analysis of changes in the transcriptome induced by daunorubicin
The Human Oncogene/Tumour Suppressor Atlas Array (BD
ClonTech) was used, in experiments performed in triplicate, to
monitor changes in the levels of transcription of 199 genes
in Jurkat T lymphocytes, with various concentrations of the
anticancer antibiotic daunorubicin, and compared with untreated
cells (see the Materials and methods section).
Treatment of early-passage Jurkat T lymphocytes with either
182 nM daunorubicin (its IC75) or 91 nM (close to the IC50 [9])
for 4 h altered gene transcription, with down-regulation of some
genes and up-regulation of others. Figure 1 shows scatter plots
of the corrected expression levels of the genes represented in the
array. They correspond to the transcription levels of daunorubicin-
treated Jurkat T cells versus untreated control cells. All the values
were corrected for the array background, and normalized by the
transcription of the housekeeping GAPDH gene. The graphic
representations in Figure 1 suggest that cells treated with various
doses of a DNA-binding drug stimulate or inhibit the expression
of a distinct set of genes depending on the concentration. We
would like to highlight that the daunorubicin concentrations used
fall within clinically relevant values [3].
In listing of daunorubicin-responsive genes, only those with
induction or repression rates equal or higher than 2.5-fold were
selected (Figure 2, upper panel). For comparison purposes, the
190 genes were grouped according to whether they were up- or
down-regulated after treatment with either drug concentration,
by using a representation that clustered several sets of genes
depending on their response to either drug dose (Figure 2,
lower panel). In this panel, the outermost and innermost circles
Figure 1 Distribution of the daunorubicin-induced expression profiles in
Jurkat T lymphocytes
Bivariate scatter plots represent, in logarithmic scales, the expression profiles of the untreated
control versus the daunorubicin-induced transcription profiles. The values are corrected
intensities in the Human Oncogene/Tumour Suppressor Atlas Array (BD ClonTech), representing
transcription profile levels. (A) Cells treated with 91 nM daunorubicin (IC50) or (B) cells treated
with 182 nM daunorubicin (IC75) for 4 h.
Table 1 A selection of differentially expressed genes in Jurkat T cells
incubated with daunorubicin
The genes displayed have been implicated previously in checkpoint arrest and apoptosis
Daunorubicin (nM)
Genes 91 182
ATM + * +
p53 + +
MDMX − =
BRCA1-associated ring domain protein 1 − +
p21WAF1 + =
N-Ras + =
p16INK4 − +
p14INK4B + +
Cyclin D3 + =
Cyclin E + −
Cdc25A + =
Rb + † +
130 kDa Rb-associated protein − =
RBQ-1 = +
RBQ-3 − +
E2F5 + +
CDC-like kinase 2 + +
* + , up-regulated ; − , down-regulated ; =, no change.
† As inferred from the semi-quantitative RT–PCR analysis (Figure 3).
display genes that changed only at one of the two concentrations
assayed. Among the 46 genes that changed with both treatments,
13 were up- or down-regulated depending on the daunorubicin
concentration. In total, 59 of the 190 genes analysed showed
opposite expression profiles at low and high drug concentrations
(cf. upper and lower panels in Figure 2). This includes genes that
are classified commonly as oncogenes or tumour suppressors,
yet most of them may provide resistance to DNA damage, or
be regarded as inducible genes involved potentially in repairing
or preventing DNA damage [23,32,33]. From the bulk of genes
that were either up- or down-regulated, Table 1 lists those
whose annotated function is related to cell-cycle progression,
arrest in G1 or G2 checkpoints, DNA damage and/or apoptosis
[32,33]. The response of many genes depended on the drug
concentration : some genes that were up-regulated at one
dose were down-regulated at the other (Figure 2). This suggests
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Figure 2 Analysis of gene expression using Human Oncogene/Tumour
Suppressor Atlas Array
Histograms represent the distribution of log2 ratio values for the genes whose transcription
profiles changed in any or both treatments with the IC50 and IC75 of daunorubicin. Genes were
grouped in two sets depending on whether their transcription profiles were affected similarly by
both treatments, or they showed differential response to the two daunorubicin concentrations
analysed. Upper panel: open bars are corrected expression profiles in the presence of 91 nM
daunorubicin and black bars correspond to corrected expression profiles in the presence of
that cell arrest and death follow a somewhat different pathway
depending on drug concentration. The names of the genes,
classified according to their response to daunorubicin, are
indicated in the legend to Figure 2. Notably, several genes,
listed in Table 1, presented expression levels clearly higher/lower
than the 2.5-fold cut-off. For example, p53, a key gene in
apoptosis, was up-regulated by approx. 14-fold in the presence of
IC75 of daunorubicin, and approx. 20-fold in the presence
of IC50, whereas cyclin E was down-regulated 50 times (IC75) but
up-regulated in the presence of the IC50. Data for all the genes
analysed are provided, as supplementary material, at the
Biochemical Journal web site. Given the relevance of several
of these genes, including p53 and Rb, to the development of the
apoptotic response [16,17,33,34], we confirmed their response to
daunorubicin by semi-quantitative RT–PCR. The transcription of
p53 was enhanced in both daunorubicin treatments (Figure 3 and
Table 1). The p53 protein acts as a transcriptional regulator for
many genes [16] and could stimulate the transcription of some
genes involved in the apoptotic pathway.
Effects of daunorubicin on cell-cycle progression
Once we established that the profiles of gene expression in Jurkat
T cells were diverse, we sought to verify whether the dose-
dependent expressions of all the genes correlated with the changes
observed in cell-cycle progression, growth arrest and cell death.
Cells treated with the two concentrations of daunorubicin were
analysed by flow cytometry to test whether the dose-dependent
expression of all the genes could correlate with the different
changes in cell-cycle progression, growth arrest and cell death.
Cell-cycle analysis of the 48 h treatment showed that the
behaviour of Jurkat T lymphocytes varied depending on the daun-
orubicin concentration (Figure 4A). At 182 nM (IC75), the drug
increased abruptly the sub-G0, which reached a peak within the
182 nM daunorubicin. Numbers on the y-axis stand for the genes tested, according to the
following list: 1, TGF-β receptor III; 2, TGF-β 2; 3, p53; 4, heregulin-β3; 5, guanine nucleotide-
binding protein α 13 subunit ; 6, pim-1; 7, Wilms’ tumour protein; 8, ski-related oncogene
snoN; 9, N-myc; 10, DCC; 11, CDC25 homologue; 12, FOS-related antigen 2; 13, ATM; 14,
PI3 kinase; 15, CDC-like kinase 2; 16, c-yes; 17, APC; 18, ETS oncogene; 19, E2F5; 20, bcl-2;
21, semaphorin III; 22, p14-INK4B; 23, RAD50 homologue; 24, neogenin; 25, CD100 antigen;
26, TGF-β signalling protein; 27, tyrosine kinase tnk 1; 28, wingless-related MMTV integration
site 2 protein; 29, junD; 30, jun-B; 31, APC; 32, v-Ki-RAS2B; 33, STAT2, STAT113; 34, erbB4;
35, mitochondrial transcription factor 1; 36, p16-INK4; 37, CBL-B; 38, 5T4 oncofoetal antigen;
39, delta lactoferrin; 40, FKBP-rapamycin associated protein; 41, frizzled homologue 5; 42,
BRCA1-associated ring domain protein 1; 43, RBQ3; 44, TATA sequence-binding protein; 45,
β 1 catenin (CTNNB); 46, cyclin E ; 47, c-kit ; 48, neuregulin 1; 49, erbB2; 50, tight junction
protein 1; 51, Rb; 52, integrin-linked kinase; 53, RBQ1; 54, semaphorin III/F ; 55, wingless-
related MMTV integration site 8b protein; 56, neurofibromatosis protein type 1; 57, neural
retin-specific leucine zipper protein; 58, MCC; 59, c-abl; 60, raf1; 61, prohibitin; 62, cyclin D3;
63, Cdc25A homologue; 64, ski; 65, TBP-associated factor 250 kDa subunit ; 66, p21/WAF1;
67, guanine nucleotide regulatory protein tim 1; 68, nuclease-sensitive element DNA-binding
protein; 69, c-fgr; 70, L-myc; 71, prefoldin 4; 72, c-kit ligand; 73, X-ray repair-complementing
defective repair in Chinese hamster cells; 74, receptor interacting protein; 75, transducer of
erbB2; 76, B-raf ; 77, prefoldin 5; 78, smoothened homologue; 79, β-catenin; 80, ZAP70;
81, CDC-like kinase 3; 82, neurogenic locus notch protein homologue 1; 83, CDC2-related
protein CHED; 84, N-Ras; 85, SAP102; 86, rel A ; 87, 130 kDa Rb-associated protein; 88,
PCTAIRE 3; 89, mdmx; 90, frizzled-related FrzB; 91, ABL2; 92, tumour necrosis factor receptor
superfamily member 10B. The function for all these genes and their accession numbers can be
found at: http://www.clontech.com/atlas. Bars labelled with arrows correspond to approximate
ratios given the low transcript values obtained in one of the experiments. Lower panel: a diagram
grouping together sets of genes according to their response to daunorubicin concentrations.
In this panel, the outermost and innermost circles display genes that changed only at one of
the daunorubicin concentrations assayed, but not at both of them. Genes represented in the
other sectors changed with both drug concentrations. + , up-regulated gene expression; −,
down-regulated gene expression; =, unchanged gene expression. In each set of two signs, the
left sign represents the lower daunorubicin concentration, and the right sign corresponds to
the higher one. Genes represented in the circles can be identified using the equivalent signs
on the proximal part of the upper panel.
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Figure 3 Differential expression of p53 and Rb in the presence of 182 or
91 nM daunorubicin as observed by semi-quantitative RT–PCR
The housekeeping GAPDH gene was co-amplified as internal control. The specific primers
used for RT–PCR amplification were: GAPDHdir, 5′-TCAGCCGCATCTTCTTTTG-3′; GAPDHrev,
5′-TGATGGCATGGACTGTGGT-3′; Rbdir, 5′-AGAACAGGAGTGCACGGATAGC-3′; Rbrev, 5′-
CGTGGTGTTCTCTGTGTTTCAA-3′; p53dir, 5′-TCAGCATCTTATCCGAGTGG-3′; p53rev,
5′-CCTGGGCATCCTTGAGTTC-3′.
first 10 h of treatment. During the 24–48 h period, cell-cycle
distribution was impaired clearly and many cells were found in
sub-G0. The cell-distribution profiles would suggest that cells
found in the S-phase underwent apoptosis after drug treatment
(Figure 4A). Continuous exposure to the IC50 daunorubicin
revealed that after 4 h treatment, most cells showed the same
distribution as controls, with a prominent G1 peak. However, in the
period up to 24 h, there was a progressive accumulation in G2/M,
followed by an undefined profile similar to the one determined
for the higher daunorubicin concentration (Figure 4A).
Dependence of apoptosis, DNA fragmentation and senescence-like
growth arrest on daunorubicin concentration
The presence of apoptotic Jurkat cells in the flow-cytometry
assays was confirmed by double staining with propidium iodide
and Annexin-V-fluos (Figure 4B). Whereas untreated controls
maintained a relatively uniform distribution throughout the
experiment, continuous treatment with 182 nM daunorubicin
increased dramatically the number of apoptotic cells, starting after
4 h (positive staining with Annexin-V-fluos) and affecting almost
25% of the cells after approx. 24 h, with another 20% of necrotic
cells. However, at the lower dose of daunorubicin, the number of
apoptotic cells increased slightly at 24 h, from 5.2 to 7.9%, and
dramatically at 48 h, from 9.62 to 24.12%. At the same time,
there was a clear increase in the number of necrotic cells and/or
secondary apoptosis (double staining with Annexin-V-fluos and
propidium iodide in Figure 4B), which reached approx. 65% of
the cell population after 48 h.
After the 4 or 10 h continuous treatment with either IC50 or IC75
for daunorubicin, cellular DNA fragmentation was also analysed
Table 2 Quantification of intracellular DNA fragmentation in Jurkat T
lymphocytes treated with various concentrations of daunorubicin
Daunorubicin (nM)
91 182
4 h 10 h 4 h 10 h
% DNA damage* 7.4 +− 5.2 7.2 +− 6.0 26.3 +− 3.1 37.8 +− 4.4
* Values are expressed as the percentage of untreated controls and represent the means +− S.D.
for three experiments.
Figure 4 Flow-cytometry analyses of Jurkat T cells incubated with
daunorubicin
(A) Cell-cycle distribution determined at the time intervals indicated. Data indicate the percentage
of cells in each phase. (B) Analysis of apoptotic cells by double staining with Annexin-V-fluos
(x-axis) and propidium iodide (y-axis) at the time intervals indicated (R1, viable cells; R2,
apoptotic cells; R3, necrotic plus secondary apoptotic cells).
by ELISA, as described in the Materials and methods section.
Cells treated with 91 nM daunorubicin hardly showed DNA
fragmentation, whereas in the presence of 182 nM daunorubicin,
DNA fragmentation increased significantly (Table 2). Taken
together, these data and the flow-cytometry results suggest that
damage of DNA by daunorubicin accelerates the susceptibility of
the cells to apoptosis. The DNA fragmentation analysed by ELISA
does not discriminate the damage produced by stabilization of the
topo II-cleavage complex and that induced by other mechanisms,
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such as free-radical formation. However, the absence of DNA
cleavage for the lower drug concentration is in keeping with
the dose-dependent effects of anthracyclines on topoisomerase
II cleavage [35].
Jurkat T cells that were halted in G2 after treatment with 91 nM
daunorubicin (Figure 4A) for 24 h showed phenotypic features of
cell senescence, such as enlarged cells and granularity together
with SA-β-gal staining [30,36] (cf. Figures 5A and 5B). The
percentage of senescent cells was approx. 40% at 24 h, which
is close to the percentage of cells that were stopped at the G2
checkpoint. After 24 h of continuous treatment, these cells were
unable to synthesize DNA, as demonstrated by the lack of BrdUrd
incorporation.
Differences in the cell distribution and time-dependent
apoptosis in cells treated with two clinically relevant daunorubicin
concentrations prompted us to test whether cells that were halted
in G2 after the 48 h treatment with daunorubicin IC50, and
were suffering replicative-like senescence (Figures 5A and 5B),
showed the morphological characteristics of apoptotic death after
longer periods of treatment, as observed after the 24 h treatment.
The morphology and the staining of Jurkat T cells studied
by fluorescence microscopy indicated that the cells underwent
delayed cell death in the presence of the lower daunorubicin
concentration, which was mainly apoptotic after 48 h (Figure 5D),
as in the presence of the higher drug concentration after the 24 h
treatment (Figure 5E).
DISCUSSION
Jurkat T lymphocytes are an especially useful cell model,
inasmuch as they are p53+ /+ and can thus suffer the
characteristic apoptosis observed in cells of lymphoid origin
in the presence of external injuries [13]. We used this system
to analyse the effects of clinically relevant concentrations of
daunorubicin, which are well below those used prevalently
Figure 5 Effects of daunorubicin on cell senescence-like growth arrest and apoptosis in Jurkat T lymphocytes
Untreated cells (A) and 91 nM daunorubicin-treated cells (B). After 24 h incubation, cells were fixed, analysed for SA-β-gal staining (a senescence marker) using a phase-contrast
microscope and photographed, after 16 h, at × 400 magnification. Approx. 35 % of the treated cells can be scored as senescent cells, whereas control cells did not show this phenotype
(approx. 1 % cells stained with SA-β-gal). The morphological analysis was performed by fluorescence microscopy, using double staining with Annexin-V-fluos and propidium iodide. (C) Untreated
cells showing no staining with propidium iodide plus Annexin-V-fluos, stained with 4,6-diamidino-2-phenylindole after 48 h. (D) Cells treated with 91 nM daunorubicin for 48 h and (E) with 182 nM
daunorubicin for 24 h. Cells in (C–E) were photographed at × 400 magnification, and they are shown at a final × 1300 magnification to display, in detail, the morphological changes characteristic
of apoptosis, which include the condensation of chromatin and the formation of apoptotic bodies.
to study drug effects on topoisomerase activity [3,35].
Daunorubicin induced cell arrest and subsequent apoptotic
death at both concentrations tested, yet the extent and the
kinetics of the apoptotic response were dose-dependent. At
the highest concentration tested, corresponding to IC75, cells
suffered apoptosis, in agreement with early observations of
apoptosis in Jurkat T cells in the presence of various
concentrations of anthracyclines [37], whereas at the lowest con-
centration, i.e. IC50, cells underwent mitotic arrest and entered
a senescence-like arrest process, and died eventually through
an apoptotic pathway. These effects were corroborated by
both flow-cytometry and standard tests for apoptosis and cell
senescence (Figures 4 and 5), suggesting two complementary
mechanisms of cell arrest induced by the antitumour antibiotic
daunorubicin.
We have used a human cDNA expression array to determine
the expression profiles of several genes classified commonly
as tumour suppressors and/or oncogenes. Our results indicate
that the fate of cells that suffered cell arrest and death after
treatment with daunorubicin may be related to the differential
expression of several key genes. Figure 6 presents a tentative
explanation of the differential effects of high and low doses of
daunorubicin by two pathways, in which the up-regulated p53
plays a central role. These pathways are based on changes in the
cell transcriptome, observed after treatment with daunorubicin
(Figure 2). There is a fair agreement between the changes
observed in the transcription of genes considered to participate
in the halt of the cell cycle in G1 or G2 (Table 1) and those
described to be involved in these checkpoints and cell arrest,
senescence-like growth arrest and apoptosis [16–18,31,34,38,39].
The pro-apoptotic factor p53, as well as ATM and Rb, was
up-regulated in both treatments, which is consistent with the
fact that the cells ended up entering apoptosis regardless of
the daunorubicin concentration. Notwithstanding, for the IC50
daunorubicin concentration, double staining with Annexin-V-
fluos and propidium iodide reflected an increase in the necrotic
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Figure 6 Two tentative pathways used to explain how the transcription profiles of the genes analysed may induce the observed final fate of Jurkat T
lymphocytes
Cells were treated with either IC75 (left panel) or IC50 (right panel) for daunorubicin. Both pathways were created considering the changes in the transcription profiles obtained by cDNA macroarray
analysis (Figure 2) and the presence of bulk DNA damage (Table 2), together with the results available on the function of the corresponding gene products on the control of cell-cycle stops in G1 or
G2/M, senescence-like growth arrest and apoptosis. Further details and references are provided in the main text. + , up-regulated; −, down-regulated. The presence of parentheses means that the
response of these genes to daunorubicin was either outside the criteria of exclusion in the analysis of gene profiles (2.5-fold change) or not corroborated in our experiments because the genes were
not present in the array.
population (Figure 4B), a result that is in keeping with the final
destiny of senescent-human fibroblasts, which predominantly
undergo necrotic death [40]. The main differences between the
two proposed pathways are based on the control of cyclin D3
and cyclin E, and their regulator p16. Treatment with IC50
for daunorubicin up-regulated both cyclins (Figure 6, right
panel), whereas the inhibitor p16 was down-regulated. The gain
of cyclin D3/cyclin E profiles together with the up-regulation of
p53, p21WAF1, ATM, cdc25A and Rb (Table 1) should induce cell
arrest at the G2/M checkpoint, as observed in the experiments
(Figure 4). From this point onwards, the transcription profiles
of p53, Rb, p16, p21WAF1 and N-Ras, whose gene expression
was altered by daunorubicin (Figure 2 and Table 1), might
be pivotal in the observed drug-induced accumulation in G2,
senescence-like growth arrest (Figure 5) and the control of the cell
programme and subsequent apoptosis, in agreement with previous
reports [14,18,31,38,39,41]. In contrast with IC75 for daunorubicin
(Figure 6, left panel), cyclin E was down-regulated, whereas p16
was up-regulated (Table 1). The resulting loss of cyclin D3/cyclin
E activity would induce cell arrest in the G1 checkpoint, thereby
causing immediate apoptosis. We propose that the main cause of
this differential regulation is the dose-dependent DNA damage,
which is known to induce cell-cycle arrest at the G1 checkpoint
[16,32,34]. DNA damage is known to stabilize the p53 protein
[34], thus facilitating progress through apoptotic pathways [26].
In addition, destabilization of the p53 protein may induce cells
under transient halt in the G2 checkpoint to re-enter the cell cycle
[18,22], committing themselves to apoptosis (Figure 5E).
Previous studies have suggested the sphingomyelin signal-
transduction pathway in daunorubicin-induced apoptosis [42]. It
has been suggested that daunorubicin and TNFα induce ceramide
accumulation [43]. However, these authors used cells treated
with much higher concentrations than those employed here; thus,
the alterations they observed in the sphingomyelin-signalling
pathway [43] are not comparable directly. We noted that some
of the transcription gene profiles of this pathway varied according
to daunorubicin concentration (Figure 2), in agreement with the
hypothesis that daunorubicin affects both apoptotic and survival
pathways [42]. The AP-1 gene that is involved in apoptosis is
up-regulated at all drug concentrations, whereas a member of
the NF-κB family (Rel A), which belongs to a pathway that
promotes survival, is only down-regulated at 91 nM daunorubicin
(Figure 2).
There are experimental grounds to consider that other cell lines
suffer non-apoptotic death and senescence in the presence of the
anthracycline doxorubicin [44], and it has been suggested that
the molecular signature of doxorubicin resistance is the expression
of certain genes [12]. Daunorubicin, doxorubicin and other DNA-
binding drugs are considered as topoisomerase II inhibitors
[3,25,35]. Therefore the possible link between the changes in
transcription after drug treatment and the introduction of DNA
breaks should be further studied. DNA damage was evident
only for the higher daunorubicin concentration (IC75; Table 2).
The higher DNA damage observed with 182 nM daunorubicin
suggests that changes in transcription gene profiles, together
with DNA damage, are fundamental to the rapid activation of
the apoptotic response. Correlation between DNA damage, cell
survival and drug exposure agrees with previous observations
using doxorubicin [35]. Daunorubicin concentrations used here
are, in general, lower than those used routinely to assay
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topoisomerase II activity (see [3] and references therein). Results
on induced DNA damage (Table 2) do not rule out that some
topoisomerase-dependent gene-specific damage is involved in
daunorubicin or doxorubicin action at low drug concentrations
[25,45]. In any case, the intercalation of daunorubicin into DNA
seems to be required for drug-inhibiting activity [45].
The elucidation of transcription profiles in tumour cells
that undergo drug-induced apoptosis, or alternative cell death
pathways, should provide potential strategies for diagnostics
and therapeutic modulation of the antiproliferative response
in cancer treatment. A known limitation of the study of the
pharmacological effects of a drug using arrays is that the effects
of a drug may not always be reflected at the transcription
level [15]. However, the association found between daunorubicin
concentration, differential gene transcription profiles, cell-cycle
distribution and ultimately apoptotic death cannot be fortuitous.
Up-regulation of p53 may play a primary role in the apoptotic
response to daunorubicin at any concentration. Daunorubicin
might act by blocking the binding of some protein factors to DNA
in vivo, as suggested using the yeast Saccharomyces cerevisiae,
in which daunorubicin inhibits gene activation by transcription
factors whose putative DNA-binding sites also contain drug-
binding sites [46]. Mechanisms other than daunorubicin binding
to DNA should be considered to understand the induced cell
arrest and apoptosis, either direct, as in topoisomerase II-mediated
cleavage of DNA, or indirect through changes in the genes
that regulate the cellular checkpoints. Nevertheless, in a recent
study aimed at detecting changes in transcription levels in the
presence of several drugs [15], all the anthracyclines clustered
together, although in a distinct position from other molecules
classified usually as topoisomerase II inhibitors, suggesting that
topoisomerase II is not the main target for low (clinically relevant)
concentrations of anthracyclines.
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